drugset / Trial / NCT07333430
Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.
Timeline
- Start
- 2026-01-15
- Primary completion
- 2027-12-01
- Completion
- 2030-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naive HBI0101 CAR-T | Cell therapy | 8e+07 cells | — |
| Subject | Naive HBI0101 CAR-T | Cell therapy | 1.6e+08 cells | — |
| Subject | Naive HBI0101 CAR-T | Cell therapy | 2.4e+08 cells | — |